Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGN 44
- Development stage
- Preclinical
- Lead developer
- Degranin Therapeutics
01
Overview
DGN 44 is a first-in-class therapeutic candidate developed by Degranin Therapeutics for the treatment of Acute Respiratory Distress Syndrome (ARDS). The drug functions by inhibiting neutrophil degranulation, a process that releases inflammatory mediators and proteases, leading to severe lung tissue damage and hyper-inflammation. By modulating this pathway, DGN 44 aims to mitigate lung injury and improve clinical outcomes in patients with ARDS, including cases triggered by viral infections such as COVID-19 and influenza. The program is currently in preclinical development and has been supported by Phase II Small Business Innovation Research (SBIR) funding.
Beyond the preview
Go deeper on DGN 44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGN 44.